Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Mar;35(1):29-34.
doi: 10.1055/s-0038-1636518. Epub 2018 Apr 5.

Locoregional Therapies for the Treatment of Hepatic Metastases from Breast and Gynecologic Cancers

Samdeep K Mouli  1 , Ramona Gupta  1 , Neil Sheth  1 , Andrew C Gordon  1 , Robert J Lewandowski  1   2   3
Affiliations
Review

Locoregional Therapies for the Treatment of Hepatic Metastases from Breast and Gynecologic Cancers

Samdeep K Mouli et al. Semin Intervent Radiol. 2018 Mar.

Abstract

Breast cancer is the most common women's malignancy in the United States and is the second leading cause of cancer death. More than half of patients with breast cancer will develop hepatic metastases; this portends a poorer prognosis. In the appropriately selected patient, there does appear to be a role for curative (surgery, ablation) or palliative (intra-arterial treatments) locoregional therapy. Gynecologic malignancies are less common and metastases to the liver are most often seen in the setting of disseminated disease. The role of locoregional therapies in these patients is not well reported. The purpose of this article is to review the outcomes data of locoregional therapies in the treatment of hepatic metastases from breast and gynecologic malignancies.

Keywords: breast cancer; chemoembolization; gynecologic malignancies; interventional radiology; liver metastases; radioembolization.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
( a ) An 82-year-old woman with a solitary tumor in the right lobe measuring 4.5 cm × 3.3 cm (arrow). This patient was treated on a clinical trial with capecitabine and radioembolization. ( b ) CT 5 months later demonstrated a reduction in bidimensional size to 1.3 cm × 1.3 cm (arrow). This patient had isolated liver metastases and remained free of extrahepatic disease 666 days after the first Y90 treatment.
See this image and copyright information in PMC

References

    1. Siegel R L, Miller K D, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(01):7–30. - PubMed
    1. Jemal A, Bray F, Center M M, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(02):69–90. - PubMed
    1. Zinser J W, Hortobagyi G N, Buzdar A U, Smith T L, Fraschini G. Clinical course of breast cancer patients with liver metastases. J Clin Oncol. 1987;5(05):773–782. - PubMed
    1. Atalay G, Biganzoli L, Renard F et al.Clinical outcome of breast cancer patients with liver metastases alone in the anthracycline-taxane era: a retrospective analysis of two prospective, randomised metastatic breast cancer trials. Eur J Cancer. 2003;39(17):2439–2449. - PubMed
    1. Cummings M C, Simpson P T, Reid L E et al.Metastatic progression of breast cancer: insights from 50 years of autopsies. J Pathol. 2014;232(01):23–31. - PMC - PubMed